Last updated: 07/17/2024 15:07:20
Assess the safety & reactogenicity of DTPa-IPV/Hib vaccine administered at 3, 4, 5 & 18 mths of age, in healthy infants
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An open, multicentric, post-marketing surveillance study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib vaccine administered at 3, 4, 5 and 18 months of age, in healthy infants.
Trial description: To assess the safety and reactogenicity of the DTPa-IPV/Hib vaccine as primary and booster vaccination. The DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo.The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of subjects reporting any solicited local and general symptoms
Timeframe: During the 4-day (Days 0-3) post-vaccination period, across doses
Secondary outcomes:
Number of subjects reporting any unsolicited adverse events (AEs)
Timeframe: During the 30-day (Days 0-29) post-vaccination period
Number of subjects reporting large injection site swelling
Timeframe: At Month 18, post-booster dose
Number of subjects reporting any serious adverse events (SAEs)
Timeframe: During the entire study period
Interventions:
Biological/vaccine: GSK Biologicals’ combined DTPa-IPV/Hib vaccine
Enrollment:
2590
Observational study model:
Not applicable
Primary completion date:
2007-23-08
Time perspective:
Not applicable
Clinical publications:
Lim FS et al. (2011) Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in post-marketing surveillance setting. Southeast Asian J Trop Med Public Health. 42(1):138-147.
Medical condition
Diphtheria, Tetanus, Poliomyelitis, acellular pertussis, Haemophilus influenzae type b, Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines
Product
SB213503
Collaborators
Not applicable
Study date(s)
November 2004 to August 2007
Type
Interventional
Phase
4
Participation criteria
Sex
Female & Male
Age
11 - 17 weeks
Accepts healthy volunteers
Yes
- Inclusion criteria
- Subjects must have been enrolled in the Rota-028 study.
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria
- Subjects must have been enrolled in the Rota-028 study.
- A male or female between, and including, 11 and 17 weeks of age at the time of the first vaccination.
- Written informed consent obtained from the parent or guardian of the subject.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol Exclusion criteria
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period.
- Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of the vaccine and ending 30 days after.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Major congenital defects or serious chronic illness.
- History of any neurologic disorders or seizures.
- Acute disease at the time of enrolment.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2007-23-08
Actual study completion date
2007-23-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website